Investigating how lipid metabolism affects cell death in brain tumors.
CDKN2A couples lipid metabolism to ferroptosis in glioblastoma
This study is looking at how changes in fat processing in brain tumors called glioblastomas might affect how the tumor cells die, with the hope of finding new ways to treat these tumors based on their unique characteristics.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11035102 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor, and aims to uncover how changes in lipid metabolism are linked to cell death in these tumors. By analyzing genetic alterations and lipid profiles from patient samples, the study seeks to identify unique metabolic signatures that could lead to new treatment strategies. The approach involves advanced techniques like next-generation sequencing and lipidomics to explore the molecular diversity of glioblastoma. Patients may benefit from insights that could inform more effective therapies tailored to their specific tumor characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma, particularly those with specific genetic alterations.
Not a fit: Patients with other types of brain tumors or those without glioblastoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve survival rates for glioblastoma patients.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer, suggesting potential for success in this novel approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Nathanson, David a. — University of California Los Angeles
- Study coordinator: Nathanson, David a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.